Optimal teicoplanin dosage regimens for methicillin-resistant Staphylococcus aureus infections in endocarditis patients and renal failure patients.

Abstract

This study aimed to assess whether traditional initial loading and maintenance doses of teicoplanin were appropriate in endocarditis and renal failure patients with methicillin-resistant Staphylococcus aureus (MRSA) infections and to recommend optimal dosage regimens. Pharmacokinetic parameters and physicochemical properties of teicoplanin were performed to develop pharmacokinetic models using GastroPlusTM. Concentration-time curves of teicoplanin in endocarditis and renal failure patients with MRSA infections were simulated by changing clearance (CL) and volume of distribution of the central compartment (Vc). Different teicoplanin dosage regimens were assessed according to the target trough concentration, and optimal teicoplanin dosage regimens were recommended. Dosage regimen of four teicoplanin doses of 6 mg/kg q12 h followed by 6 mg/kg qd is recommended for renal failure patients infected by MRSA. And optimal dosage regimen is five teicoplanin doses of 15 mg/kg q12 h followed by doses of 12 mg/kg qd for endocarditis patients infected by MRSA.

• Authors: Na Li, Liqin Zhu, Gaoqi Xu, Tingyue Ge, Fang Qi, Mengxue Li
• Journal: Journal of chemotherapy (Florence, Italy) (J Chemother) Vol. 29 Issue 6 Pg. 358-364 (Dec 2017) ISSN: 1973-9478 [Electronic] England
• PMID: 28587526 (Publication Type: Journal Article)

Chemical References

• Anti-Bacterial Agents
• Teicoplanin

Topics

• Anti-Bacterial Agents (pharmacokinetics)
• Endocarditis, Bacterial (microbiology)
• Humans
• Methicillin-Resistant Staphylococcus aureus
• Models, Theoretical
• Renal Insufficiency (microbiology)
• Staphylococcal Infections (drug therapy)
• Teicoplanin (pharmacokinetics)